Executive Meetings. Prior to submitting any dispute or controversy arising from or in connection with this Agreement, including the breach, termination or invalidity thereof (a “Dispute”), to arbitration pursuant to Section 16(b)(ii), upon written request of any Party, each Party shall appoint a designated representative whose task it will be to meet promptly for the purpose of endeavoring to resolve such Dispute. The designated representatives shall meet, in person or by telephone or video conference as deemed appropriate by the Parties, as often as the Parties reasonably deem necessary to discuss the Dispute in an effort to resolve the Dispute without the necessity of any further proceeding. The Parties agree to negotiate, in good faith, in an attempt to resolve the Dispute for a period of not greater than thirty (30) days after notice of the Dispute is received by the Parties.
Executive Meetings. To support working together in partnership the OU and the Students Association will provide opportunities for regular meetings between Association managers and members of the Central Executive Committee and their counterparts in the senior management of the OU. Meetings should take place wherever the conduct of the business of the University may be enhanced by the direct involvement of student representatives and, similarly, where the conduct of Association business may be enhanced by the direct involvement of OU staff and officers. The Pro Vice-Chancellor (Students) and Association President are the senior representatives of the OU and the OU Students Association respectively who are responsible for managing the development of the relationship between the organisations.
Executive Meetings. The Executive Board shall comprise of the elected officers, excepting Trustees. 50% of the Executive Board shall constitute a quorum for the purpose of executive meetings. The Executive Board shall meet at least once a month.
Executive Meetings. FibroGen’s Chief Executive Officer and an appropriate Executive Vice President of AstraZeneca (or other appropriate representative of AstraZeneca of equivalent seniority) will meet in advance of the occurrence of key scheduled Development and Commercialization events or in connection with key decisions, to review and discuss the status and direction of the Collaboration.
Executive Meetings. The Vice President, Business and Commercial Development of Targacept (or such other officer with comparable seniority and responsibility with respect to Targacept’s promotional activities as Targacept may designate in writing to AstraZeneca from time to time) and the Vice President, Commercial Operations of AstraZeneca Pharmaceuticals, LP (or such other officer with comparable seniority and responsibility with respect to AstraZeneca’s promotional activities as AstraZeneca may designate in writing to Targacept from time to time) shall meet at least semi-annually to review the Exploitation of any Co-Promoted Products.
Executive Meetings. No less than once per Calendar Year, FibroGen Cayman’s Chief Executive Officer and AstraZeneca’s Marketing Company President will meet in advance of the occurrence of key scheduled Development and Commercialization events or in connection with key decisions, to review and discuss the status and direction of the collaboration in the Territory.
Executive Meetings. 15.01 Procedures laid down in Xxxxxxx Rules of Order shall be used as a guideline to conduct all proceedings of the MRSA.
15.02 The Executive shall hold regular meetings throughout the year. No meeting of the Executive shall be held without a quorum of four (4) members of the Executive.
15.03 Voting on motions in Executive meetings shall require a quorum of seven (7) members of the Executive.
15.04 All members of the Executive have one (1) vote each except the Board of Governors Representative and the Past President who have no voting rights. In the event of a tie, the President shall cast the deciding vote.
15.05 In the event that any Executive member engages in disorderly conduct during a meeting, the President or Vice-President may expel him from the meeting and the remaining members shall constitute a quorum, provided at least six individuals remain in the meeting. The decision of the President or Vice- President shall be final and not subject to any appeal.
15.06 Should any Executive member fail to be present for three (3) consecutive meetings without having good and sufficient cause for their absence, their office may be declared vacant by vote of the Executive and the position shall be filled by the method described in the MRSA policies. If ten (10) days after notification of the vacancy no member comes forward to stand for election, the Executive may appoint a replacement who shall serve for the remainder of the term.
Executive Meetings. The Parties anticipate that the Chief Executive Officer of Ironwood and AstraZeneca’s Regional Vice President of Asia Pacific will meet periodically as necessary or appropriate during the Term (and in any event such executives will meet at least once per Year in person) in order to review significant issues and developments in the Development, Manufacture and Commercialization of Products in the Territory. [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Executive Meetings. One (1) civilian member of the Association will be allowed two (2) consecutive days and essential traveling time, with no loss of salary, to attend three (3) two (2) day executive meetings of the O.S.O.P.A. or for training purposes per year, at the discretion of the Chief of Police or designate.
Executive Meetings. Intel and Cymer agree they will regularly schedule executive reviews of the EUV Source System(s) technology development plan and the schedule (“Executive Meetings”). The Executive Meetings will occur […***…] until Cymer makes the first HVM Source available for shipment. The agenda of such Executive Meetings will be mutually agreed in advance thereof, including without limitations, roadmaps, schedule requirements, non-binding unit forecast, waivers to […***…] (such waiver(s) to be at Intel’s sole discretion), resolution of corrective action requests to Intel’s reasonable satisfaction, Cymer program spending/funding (including anticipated sale of Beta Minus Source and Beta Source) and NRE payments (which may be changed by mutual agreement in the event it appears to the Parties that new technical or commercial issues warrant such change). If necessary, the timing of […***…] as set forth in Section 5 shall be changed to align with any agreed upon roadmap and/or schedule changes.
